Contact
Please use this form to send email to PR contact of this press release:
Rafael Pharmaceuticals Announces Expansion into France of Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) in Combination with Modified FOLFIRINOX as First-Line Treatment for Patients with Metastatic Pancreatic Cancer
TO: